glucagon-like peptide-1 agonist

Overview

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs, also called incretin mimetics) are a class of injectable and oral drug therapies used to treat type 2 diabetes and obesity. They are peptide-based analogues of the endogenous incretin hormone glucagon-like peptide-1, which is secreted by intestinal L-cells after nutrient ingestion but is rapidly degraded by dipeptidyl peptidase-4 (DPP-4). Therapeutic agents in this class are engineered to resist that degradation, giving them a duration of action long enough for daily or weekly dosing. Widely used members include exenatide, liraglutide, and semaglutide, the last available in both subcutaneous and oral formulations; tirzepatide extends the approach as a dual agonist that also activates the glucose-dependent insulinotropic polypeptide (GIP) receptor.

These drugs act at the GLP-1 receptor, a G protein-coupled receptor expressed on pancreatic beta cells and in the central nervous system as well as in cardiac, renal, vascular, and gastrointestinal tissue. Receptor activation stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite through hypothalamic and brainstem signalling — a combination that lowers blood glucose with low intrinsic hypoglycaemia risk while producing substantial weight loss. Because the receptor is expressed well beyond the pancreas, clinical interest has broadened past glycaemic control to cardiovascular disease, obstructive sleep apnea, chronic kidney disease and preservation of glomerular filtration rate, metabolic dysfunction–associated steatotic liver disease, and inflammatory conditions, with additional exploratory work in areas such as pulmonary arterial hypertension, neurodegeneration, and cancer outcomes. In practice GLP-1 RAs are positioned alongside metformin, Insulin Therapy, sodium-glucose cotransporter-2 (SGLT2) inhibitors, DPP-4 inhibitors, and bariatric metabolic surgery, and comparative and combination studies against these alternatives are an active focus of cardiometabolic research.

Recent Publications Summary (latest 30 papers)

Recent publications demonstrate that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide significant cardiovascular and metabolic benefits across diverse patient populations with type 2 diabetes. In a large Japanese claims database study of 469,461 patients, GLP-1RA use was associated with reduced cardiovascular and cerebrovascular events and improved all-cause mortality compared with other glucose-lowering agents 42581431Aug. Real-world comparative analyses using propensity score matching and Cox proportional hazards modeling confirmed that GLP-1 RAs sustained improvements in glycemic control and reduced all-cause mortality versus dipeptidyl peptidase-4 inhibitors 41741950Feb, with cardiovascular effectiveness comparable to sodium-glucose cotransporter-2 inhibitors 41984016Apr. In Japanese patients with type 2 diabetes and obesity, both SGLT2 inhibitors and GLP-1 receptor agonists demonstrated renoprotective effects, though differential renal outcomes were observed based on blood pressure reduction patterns 41838277Mar. Among Hispanic adults in community primary care, monotherapy with GLP-1 receptor agonists achieved glycemic control (HbA1c ≤7%) in ≥85% of patients, representing some of the highest efficacy rates across available glucose-lowering agents 41987878Apr.

Glucagon-like peptide-1 receptor agonists have emerged as a major therapeutic option for weight loss in overweight and obesity, though clinical implementation faces several challenges. A Swedish cross-sectional survey of primary care physicians found varied attitudes toward GLP-1 RA use for obesity management 42557543Aug, while a US national survey of GLP-1 RA discontinuers identified that more than half discontinued therapy within 6 months and 79.7% within 12 months, with multiple self-reported reasons for discontinuation 42504813Jul. Long-term health care utilization cost analyses comparing GLP-1 RAs with bariatric metabolic surgery are currently underway to clarify the economic impact 42384380Jul. Importantly, combining GLP-1 receptor agonists with structured health behavior and lifestyle therapy in adolescents with obesity yielded higher adherence and reduced session needs for successful weight management 42222894Jun. State-level variation in GLP-1RA utilization reflects differences in disease prevalence and state-level coverage policies 42043919Apr, and recent economic analyses indicate that while semaglutide and tirzepatide demonstrate cost-effectiveness compared with lifestyle modification alone, real-world persistence rates are lower than in clinical trials, resulting in weight regain after discontinuation and mixed evidence on long-term medical cost offsets 42166309May.

Beyond glycemic control, GLP-1 receptor agonists show therapeutic promise in metabolic dysfunction-associated steatotic liver disease (MASLD) and related conditions. Combined GLP-1RA plus SGLT2 inhibitor therapy demonstrated potential synergistic benefits for liver fibrosis progression in patients with MASLD and type 2 diabetes 41974037Apr. Incretin therapies including GLP-1 receptor agonists are increasingly emphasized in MASLD management due to their systemic cardiometabolic benefits and relevance to cardiovascular-kidney-metabolic syndrome 42144672May. In patients with MASLD and type 2 diabetes at high cardiovascular risk, GLP-1 receptor agonists provided cardiovascular protection comparable to SGLT2 inhibitors 41802676Mar. Additionally, GLP-1 receptor agonists displayed pleiotropic anti-inflammatory effects with potential clinical impact in adults with Crohn's disease and comorbid obesity, where initiation was evaluated for associations with mortality, health care utilization, and treatment intensity 42321339Jun.

Recent studies document GLP-1 receptor agonist effects in specialized populations and previously unexplored clinical contexts. In a real-world cohort of kidney transplant recipients with type 2 diabetes, GLP-1RA treatment over 5 years yielded statistically significant reductions in weight (up to 4.1 kg), HbA1c levels, and major adverse cardiovascular events, with MACE rates declining from 45.5% at initiation to 18.9% during follow-up 41841288Mar. Glucagon-like peptide-1 receptor agonists demonstrated cardiovascular risk modification potential in patients with obstructive sleep apnea and obesity, where they may reduce cardiovascular events 42387223Jul, and showed promise in reducing cardiovascular risk in people living with HIV presenting with excess visceral abdominal fat 42139091May. Preclinical and exploratory clinical evidence suggests additional neuroprotective mechanisms; GLP-1 receptor agonists including semaglutide, tirzepatide, and liraglutide inhibited amyloid-β42 aggregation by targeting primary nucleation, potentially offering therapeutic relevance for Alzheimer's disease 42133988May. First-in-disease acute hemodynamic studies of the GLP-1 agonist exenatide in pulmonary arterial hypertension showed favorable tolerability and improvements in pulmonary hemodynamics and cardiac function 42171611May. In bladder cancer patients, GLP-1RA exposure was examined for associations with overall survival 42224918Jun.

The safety profile of GLP-1 receptor agonists continues to be refined through large real-world studies. A target trial emulation using electronic health records examined the association between GLP-1 receptor agonists and incident alopecia (hair loss) in adults with type 2 diabetes 42486607Jul, while retrospective cohort analyses evaluated associations with hepatic decompensation compared with DPP-4 inhibitors in racially and ethnically diverse populations 41847743Mar. Notably, GLP-1 receptor agonists demonstrated anti-inflammatory and wound-healing properties that significantly decreased the risk of postoperative complications following dermatologic surgery 42210885May. Regarding bone health, large-scale target trial emulation studies compared femur fracture risk between GLP-1 receptor agonists and DPP-4 inhibitors in type 2 diabetes patients 41819195Mar, and examined the risk of fragility fractures in older adults receiving GLP-1RAs 41665888Feb. Additionally, GLP-1 receptor agonists were evaluated for their association with nonarteritic anterior ischemic optic neuropathy versus DPP-4 inhibitors in type 2 diabetes 41701611Feb. Novel formulation strategies, including pullulan-based bilayer films for buccal delivery, are being developed to provide non-injectable administration routes for GLP-1 receptor agonist analogues 41831981Mar. Comparative effectiveness research indicates that tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, demonstrated superior metabolic efficacy for preventing progression to advanced cardiovascular-kidney-metabolic stages compared with conventional GLP-1 receptor agonists 42009260Apr.

What Changes, What Holds

1. Real-world effectiveness against other glucose-lowering agents shows comparable cardiovascular outcomes
REINFORCES Propensity-matched cohorts and database studies of nearly 470,000 patients confirm GLP-1 RAs reduce cardiovascular and cerebrovascular events and mortality versus DPP-4 inhibitors 42581431Aug41741950Feb with outcomes matching SGLT2 inhibitors. These pragmatic, large-scale findings in diverse real-world populations ground what trials suggested, confirming the established cardiometabolic research focus without shifting the underlying understanding of benefit.

2. High real-world discontinuation rates and weight regain after stopping therapy
NEW DIRECTION More than half of GLP-1 RA users discontinued within 6 months, 79.7% within 12 months 42504813Jul, with weight returning after discontinuation 42166309May. The Overview treats GLP-1 RAs as disease-modifying agents, but these persistence patterns reveal therapeutic effect requires ongoing use rather than conferring lasting metabolic change. Cost-effectiveness versus bariatric surgery thus hinges on long-term continuation—a durability challenge the baseline does not acknowledge.

3. Established benefits in liver disease and emerging anti-inflammatory effects in Crohn's disease
REINFORCES GLP-1 RAs demonstrate pleiotropic anti-inflammatory effects with potential benefit in Crohn's disease and obesity 42321339Jun, while combined GLP-1RA plus SGLT2i therapy shows synergistic benefits for liver fibrosis 41974037Apr. The Overview foreshadows GLP-1 RA interest in inflammatory conditions and MASLD through exploratory work; these findings evidence those predicted areas while confirming cardiometabolic-kidney-metabolic relevance the baseline already implies.

4. Kidney transplant recipients emerge as a therapeutic population with reduced major adverse cardiovascular events
NEW DIRECTION A five-year real-world cohort of kidney transplant recipients showed major adverse cardiovascular events declining from 45.5% to 18.9% with GLP-1RA treatment 41841288Mar, establishing benefit in a patient population the Overview does not mention. This finding, alongside emerging cardiovascular risk modification in people living with HIV 42139091May and neuroprotective mechanisms potentially relevant to Alzheimer's disease, expands therapeutic contexts beyond the exploratory areas the baseline foreshadows.

5. safety monitoring expands to alopecia, bone fractures, and optic neuropathy
NEW DIRECTION Real-world trial emulation and retrospective cohort analyses identified potential safety signals in alopecia and bone fractures 42486607Jul41819195Mar across diverse populations, expanding monitored adverse events into tissues the Overview does not address. Conversely, documented anti-inflammatory and wound-healing properties reduced postoperative surgical complications, while novel buccal delivery formulations and tirzepatide efficacy comparisons represent pharmacologic advances. The safety profile now extends in both harmful and beneficial directions the baseline omits, without contradicting established efficacy.

Overview update candidates: real-world discontinuation rates and weight regain after stopping therapy; kidney transplant recipients as an emerging therapeutic population.